Skip to Content

The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic

In this MEDtalk Lara Van Der Schoot and Juul van den Reek, both Radboud Institute for Health Sciences and Department of Dermatology, The Netherlands, discuss the risk of COVID-19 in psoriasis patients treated with biologics, and whether there is a differential risk of infections between the biologics targeting different interleukins.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top